NxStage to Present at the Canaccord Genuity 32nd Annual Growth Conference

Friday August 10, 2012

LAWRENCE, Mass., Aug. 10, 2012 /PRNewswire/ — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer, will present at the Canaccord Genuity 32nd Annual Growth Conference on Tuesday, August 14th, at 4:30 p.m. ET. A webcast of the event will be made available at http://ir.nxstage.com/ at the time of the presentation.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company’s website at http://www.nxstage.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to Mr. Burbank‘s plans to present at this conference. NxStage specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing NxStage’s expectations or beliefs as of any date subsequent to the date of this press release.

Contact:
Kristen K. Sheppard, Esq.
Investor Relations
ksheppard@nxstage.com

SOURCE NxStage Medical, Inc.

News Provided by Acquire Media